Published in J Med Chem on February 28, 1997
A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A (2006) 2.08
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci (2010) 1.78
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A (2006) 1.52
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A (2001) 1.41
The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol (2005) 1.38
Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem (2008) 1.37
Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol (2012) 1.31
The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem (2009) 1.28
Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J (2001) 1.14
Identification of endogenous acyl amino acids based on a targeted lipidomics approach. J Lipid Res (2010) 1.12
'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol (2008) 1.09
Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis (2010) 1.08
Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res (2010) 1.08
Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol (2007) 1.07
Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol (2001) 1.07
Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J (2009) 1.07
Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin Chem Lab Med (2008) 1.06
Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol (2004) 1.04
N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br J Pharmacol (2010) 1.04
Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.03
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
N-Docosahexaenoylethanolamide promotes development of hippocampal neurons. Biochem J (2011) 1.01
Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol (2009) 1.01
Targeted lipidomics: discovery of new fatty acyl amides. AAPS J (2006) 0.99
Fatty acid amide signaling molecules. Bioorg Med Chem Lett (2010) 0.98
Actions of N-arachidonyl-glycine in a rat inflammatory pain model. Mol Pain (2007) 0.98
Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology (2007) 0.97
Potential anti-inflammatory actions of the elmiric (lipoamino) acids. Bioorg Med Chem (2007) 0.97
Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol (2013) 0.96
A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. Prostaglandins Other Lipid Mediat (2011) 0.96
Resolution of inflammation by N-arachidonoylglycine. J Cell Biochem (2011) 0.96
Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem (2010) 0.95
N-Docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation. J Neurochem (2013) 0.93
Orphan endogenous lipids and orphan GPCRs: a good match. Prostaglandins Other Lipid Mediat (2009) 0.92
N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol (2010) 0.91
GPR18 in microglia: implications for the CNS and endocannabinoid system signalling. Br J Pharmacol (2012) 0.91
Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J Biol Chem (2011) 0.91
Design and synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel endocannabinoids. Chemistry (2010) 0.90
Metabolomics uncovers dietary omega-3 fatty acid-derived metabolites implicated in anti-nociceptive responses after experimental spinal cord injury. Neuroscience (2013) 0.89
The elmiric acids: biologically active anandamide analogs. Neuropharmacology (2007) 0.88
So what do we call GPR18 now? Br J Pharmacol (2012) 0.87
Synaptamide, endocannabinoid-like derivative of docosahexaenoic acid with cannabinoid-independent function. Prostaglandins Leukot Essent Fatty Acids (2012) 0.87
Development of novel tail-modified anandamide analogs. Bioorg Med Chem Lett (2008) 0.87
Mechanisms of exercise-induced hypoalgesia. J Pain (2014) 0.86
siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration. J Mol Signal (2012) 0.86
N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal horn. Br J Pharmacol (2010) 0.86
Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts. Front Physiol (2014) 0.84
N-Acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids - from fishy endocannabinoids to potential leads. Br J Pharmacol (2013) 0.84
Inhibition of COX-2-mediated eicosanoid production plays a major role in the anti-inflammatory effects of the endocannabinoid N-docosahexaenoylethanolamine (DHEA) in macrophages. Br J Pharmacol (2014) 0.83
Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Philos Trans R Soc Lond B Biol Sci (2012) 0.82
Dietary DHA reduces downstream endocannabinoid and inflammatory gene expression and epididymal fat mass while improving aspects of glucose use in muscle in C57BL/6J mice. Int J Obes (Lond) (2015) 0.82
GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine. PeerJ (2016) 0.81
Long-term consequences of perinatal fatty acid amino hydrolase inhibition. Br J Pharmacol (2014) 0.81
Further advances in the synthesis of endocannabinoid-related ligands. AAPS J (2005) 0.81
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. J Biol Chem (2014) 0.81
The endocannabinoid N-arachidonoyl glycine (NAGly) inhibits store-operated Ca2+ entry by preventing STIM1-Orai1 interaction. J Cell Sci (2012) 0.80
Cannabinoid CB1 receptor recognition of endocannabinoids via the lipid bilayer: molecular dynamics simulations of CB1 transmembrane helix 6 and anandamide in a phospholipid bilayer. J Comput Aided Mol Des (2006) 0.80
N-Arachidonoyl glycine suppresses Na⁺/Ca²⁺ exchanger-mediated Ca²⁺ entry into endothelial cells and activates BK(Ca) channels independently of GPCRs. Br J Pharmacol (2013) 0.78
N-Amino acid linoleoyl conjugates: anti-inflammatory activities. Bioorg Med Chem Lett (2011) 0.78
Do N-arachidonyl-glycine (NA-glycine) and 2-arachidonoyl glycerol (2-AG) share mode of action and the binding site on the β2 subunit of GABAA receptors? PeerJ (2013) 0.76
The cannabinoid acids, analogs and endogenous counterparts. Bioorg Med Chem (2014) 0.76
Characterization of non-olfactory GPCRs in human sperm with a focus on GPR18. Sci Rep (2016) 0.75
Synthesis of 2-(5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenamidoethyl-d(4) Dihydrogen Phosphate, Tetra-deuterated pAEA. J Labelled Comp Radiopharm (2008) 0.75
Asymmetric synthesis of novel N-(1-phenyl-2,3-dihydroxypropyl)arachidonylamides and evaluation of their anti-inflammatory activity. Life Sci (2012) 0.75
Anti-inflammatory ω-3 endocannabinoid epoxides. Proc Natl Acad Sci U S A (2017) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Acetylcholine receptors of muscle grown in vitro. Proc Natl Acad Sci U S A (1972) 3.96
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Development of acetylcholine receptor clusters on cultured muscle cells. Proc Natl Acad Sci U S A (1973) 2.71
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology (1980) 2.41
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
Marihuana chemistry. Science (1970) 2.10
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Chemical basis of hashish activity. Science (1970) 1.94
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
Myasthenia gravis: a serum factor blocking acetylcholine receptors of the human neuromuscular junction. Lancet (1975) 1.84
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol (1998) 1.83
Early medical use of cannabis. Nature (1993) 1.80
Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. Proc Natl Acad Sci U S A (1993) 1.75
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol (1993) 1.73
A factor from neurons increases the number of acetylcholine receptor aggregates on cultured muscle cells. Proc Natl Acad Sci U S A (1978) 1.66
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Discovery and characterization of endogenous cannabinoids. Life Sci (1999) 1.56
Functional role of proline and tryptophan residues highly conserved among G protein-coupled receptors studied by mutational analysis of the m3 muscarinic receptor. EMBO J (1993) 1.56
Anandamide may mediate sleep induction. Nature (1997) 1.53
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol (1997) 1.49
The inactivation and reactivation of Escherichia coli ribosomes. Methods Enzymol (1974) 1.45
The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc (1971) 1.44
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem (1993) 1.44
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol (1992) 1.44
Immunoperoxidase staining of alpha-bungarotoxin binding sites in muscle endplates shows distribution of acetylcholine receptors. Nature (1975) 1.42
Biphasic effects of anandamide. Pharmacol Biochem Behav (1998) 1.41
Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst (1967) 1.40
Localization of acetylcholine receptors during synaptogenesis in retina. Proc Natl Acad Sci U S A (1976) 1.38
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett (1967) 1.30
Identification of synaptic acetylcholine receptor sites in retina with peroxidase-labeled alpha-bungarotoxin. Proc Natl Acad Sci U S A (1977) 1.29
Synapse and acetylcholine receptor synthesis by neurons dissociated from retina. Proc Natl Acad Sci U S A (1976) 1.26
Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol (2000) 1.23
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity (2006) 1.22
Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J Biol Chem (1997) 1.21
Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J Neurochem (1998) 1.21
A historical overview of chemical research on cannabinoids. Chem Phys Lipids (2000) 1.20
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett (1995) 1.20
An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci (1995) 1.20
Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem (1993) 1.20
-Bungarotoxin used as a probe for acetylcholine receptors of cultured neurones. Nature (1973) 1.19
Pharmacological effects of two active constituents of marihuana. Arch Int Pharmacodyn Ther (1968) 1.18
Toward drugs derived from cannabis. Naturwissenschaften (1978) 1.17
The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell (1995) 1.17
A novel probe for the cannabinoid receptor. J Med Chem (1992) 1.16
Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. J Biol Chem (1996) 1.16
Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav (1989) 1.15
(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem (1996) 1.15
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem (1997) 1.15
Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J (2001) 1.14
2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol (2000) 1.13
Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci U S A (1994) 1.13
Antipsychotic effect of cannabidiol. J Clin Psychiatry (1995) 1.13
Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. J Biol Chem (1992) 1.12
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol (2012) 1.11
Adenylylcyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. J Biol Chem (1995) 1.11
On the specificity and stability of an enzyme that hydrolyzes N-substituted aminoacyl-transfer RNA's. Proc Natl Acad Sci U S A (1968) 1.10
Ras-GRF, the activator of Ras, is expressed preferentially in mature neurons of the central nervous system. Brain Res Mol Brain Res (1997) 1.10
The possible involvement of peptidyl transferase in the termination step of protein biosynthesis. Biochemistry (1969) 1.08
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release (2003) 1.06
Suppressors of cancer cell proliferation from fig (Ficus carica) resin: isolation and structure elucidation. J Nat Prod (2001) 1.05
Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron (1965) 1.05
Ultrastructure of acetylcholine receptor clusters on cultured muscle fibers. J Cell Biol (1976) 1.03
Correlation between the peptidyl transferase activity of the 50 s ribosomal subunit and the ability of the subunit to interact with antibiotics. J Mol Biol (1971) 1.03
Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem (1998) 1.02
Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther (1989) 1.02
A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol (2008) 1.02
Identification through synthesis of an active delta-1(6)-tetrahydrocannabinol metabolite. J Am Chem Soc (1970) 1.02
Laminin induces acetylcholine receptor aggregation on cultured myotubes and enhances the receptor aggregation activity of a neuronal factor. J Neurosci (1983) 1.02
How the mongoose can fight the snake: the binding site of the mongoose acetylcholine receptor. Proc Natl Acad Sci U S A (1992) 1.02
Kappa-opiate agonists inhibit adenylate cyclase and produce heterologous desensitization in rat spinal cord. J Neurochem (1989) 1.01
Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem (1992) 1.01
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol (2001) 1.01
Reconstitution of functional muscarinic receptors by co-expression of amino- and carboxyl-terminal receptor fragments. FEBS Lett (1993) 1.01
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun (1997) 1.00
Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology (1990) 0.99
Ribosome activation and the binding of dihydrostreptomycin: effect of polynucleotides and temperature on activation. J Mol Biol (1970) 0.99
The chemistry of endocannabinoids. J Endocrinol Invest (2006) 0.99
Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs. Cell Mol Neurobiol (1999) 0.99
Opioids inhibit endothelin-mediated DNA synthesis, phosphoinositide turnover, and Ca2+ mobilization in rat C6 glioma cells. J Neurosci (1994) 0.98
Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol (1994) 0.97
Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats. Circulation (1996) 0.97